Corpus Intelligence IC Memo — BLIANT SPRCIALTY HOSPITAL 2026-04-26 06:38 UTC
IC Memo — BLIANT SPRCIALTY HOSPITAL
Investment Committee Memorandum | LA | 21 beds | Grade D | EBITDA uplift $209K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BLIANT SPRCIALTY HOSPITAL

CCN 192030 | ORLEANS PARISH, LA | 21 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

BLIANT SPRCIALTY HOSPITAL is a 21-bed rural/critical access in ORLEANS PARISH, LA with $2.6M in net patient revenue and a 2.7% operating margin. The hospital serves a payer mix of 64.5% Medicare, 35.5% Medicaid, and 0.0% commercial.

Thesis: Turnaround. Our ML models identify $209K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.7% to 10.6% (+792bps).

Net Revenue HCRIS$2.6M
Current EBITDA COMPUTED$70K
Operating Margin COMPUTED2.7%
Occupancy HCRIS28.5%
Revenue / Bed COMPUTED$126K
Net-to-Gross HCRIS60.2%
Distress Probability ML66.6%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
121
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 2.7% places it above the state median. Among 121 size-comparable peers (10-42 beds), the median margin is -2.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-42), prioritizing same-state peers. 121 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BLIANT SPRCIALTY HOSPITAL (Target)LA21$2.6M2.7%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%
THE SPINE HOSPITAL OF LOUISIANLA23$57.4M35.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $209K (792bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Denial Rate Reduction12.0%6.5%$59K+224bp12mo
Net Collection Rate93.5%97.0%$55K+210bp18mo
Cost to Collect4.5%2.5%$53K+200bp12mo
A/R Days Reduction5200.0%3800.0%$32K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+36bp6mo

5. EBITDA Bridge

Denial Rate Reduction
$59K
Net Collection Rate
$55K
Cost to Collect
$53K
A/R Days Reduction
$32K
Clean Claim Rate
$10K
Total EBITDA Uplift$209K
Current EBITDA$70K
+ RCM Uplift+$209K
Pro Forma EBITDA$279K
Current Margin2.7%
Pro Forma Margin10.6%
WC Released (1x)$101K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$108K$2.6M23.56x88.1%
Base (11x exit)10.0x11.0x$108K$2.8M26.24x92.2%
Bull Case9.0x11.0x$98K$3.6M36.59x105.4%
Bull (12x exit)9.0x12.0x$98K$3.9M40.21x109.3%
Bear Case11.0x10.0x$119K$1.5M12.36x65.4%
Bear (11x exit)11.0x11.0x$119K$1.7M13.92x69.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 64.5% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
MediumElevated Medicaid exposure (35.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
MediumLow occupancyAt 28.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 66.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 121 hospitals with 10-42 beds
  • Same-state prioritization (n=122)
  • Comp margins: P25=-15.0% / P50=-2.3% / P75=6.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.